Corcept.

Dec 31, 2021 · MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2021. Corcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking StatementsWebCorcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...Web7 Okt 2022 ... Corcept Therapeutics Extends Exclusive Specialty Pharmacy Distribution Agreement for Korlym with Optime Care.Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, reported results for the quarter ended June 30, 2023.

Read Our Latest Stock Report on Corcept Therapeutics. Corcept Therapeutics Stock Performance. CORT stock opened at $25.97 on Monday. Corcept Therapeutics has a one year low of $17.86 and a one ...WebCorcept Therapeutics Incorporated's CORT only marketed drug, Korlym, has been approved for the once-daily oral treatment of hyperglycemia — secondary to hypercortisolism — in adult patients ...

Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.WebCorcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical …Web

Apr 7, 2022 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ... Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...Sep 9, 2021 · Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone ... Dec 1, 2023 · Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more. On November 2, 2023, Joseph Lyon, the Chief Accounting Officer of Corcept Therapeutics Inc (NASDAQ:CORT), sold 5,000 shares of the company. Find the latest Corcept Therapeutics Incorporated (CORT ...Web

MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today …Web

Jun 29, 2022 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...

Jul 28, 2020 · About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ... 2015-10000 12/17/2015 Closed LATHAM & WATKINS LLP 11104397 11063344 10989897 ETC 2015-10001 Steptoe & Johnson LLP FAP 2258 2015-10002 HemoCue AB K142209About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...Hazel Hunt, Mark Strem, and Joseph Belanoff are employees and shareholders of Corcept Therapeutics. The study was conducted at Quotient Clinical. Vanessa Zann, Pui Leung, Suzanne Sweet, and Alyson Connor are employees of Quotient Clinical. Kirsteen Donaldson and Dan Combs are paid consultants of Corcept …About Corcept. Executive Team. Board of Directors. Educational Grants. Contact Us. 149 Commonwealth Drive, Menlo Park, CA 94025. Phone: 650-327-3270. Email: [email protected]. Contact us with questions about Corcept, for more information about the company, or where we are located. Corcept’s third quarter 2022 revenue was $101.7 million, compared to $96.1 million in the third quarter of 2021. Third quarter operating expenses were $69.8 million , compared to $59.9 million in the third quarter of 2021, due to increased clinical trial and …We are confident in the growth potential of our Cushing’s syndrome business and are raising our 2023 revenue guidance again, to $455 - $470 million,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. Corcept’s second quarter 2023 revenue was $117.7 million, compared to $103.4 million in the second quarter of 2022.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects.Apr 7, 2022 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ... Dec 20, 2021 · Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone ... Nov 2, 2023 · We are raising our 2023 revenue guidance again to a range of $470 million to $480 million, up from $455 million to $470 million. Net income was $31.4 million or $0.28 per share in the third ... Dec 20, 2021 · Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone ...

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...In accordance with the terms and conditions of the Tender Offer, based on these preliminary results, Corcept expects to purchase 6,630,151 shares of common stock at a purchase price of $22.00 per ...

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and …WebChallenging work environment ... Corcept offers some decent benefits and a high salary for a reason. Corcept seems to think they offer the best benefits package, ...Corcept’s second quarter 2022 revenue was $103.4 million, compared to $91.6 million in the second quarter of 2021. Second quarter operating expenses were $72.0 million , compared to $59.6 million in the second quarter of 2021, due to increased clinical trial activity, expenses to support the expansion of our clinical development and ...WebJul 17, 2023 · Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements. Feb 28, 2023 · Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements. Cortisol. Cortisol is a hormone that modulates many physiological and psychological processes. Because of its central role in the body’s response to stress, cortisol is most commonly known as the stress hormone. It plays a key role in regulating metabolism and maintaining normal blood pressure. It affects both cognition and emotional state. Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking Statements.WebDec 31, 2022 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...

Jun 30, 2022 · Corcept’s second quarter 2022 revenue was $103.4 million, compared to $91.6 million in the second quarter of 2021. Second quarter operating expenses were $72.0 million , compared to $59.6 million in the second quarter of 2021, due to increased clinical trial activity, expenses to support the expansion of our clinical development and ...

Corcept conducted the drug-drug interaction study de-scribed in Lee, collecting data on co-administration of mif-epristone with a strong CYP3A inhibitor. Based on that data, Corcept sought and received the ’214 patent . The ’214 patent relates to methods of treating Cushing’s syndrome by co-administering mifepristone and a strong CYP3A in-

MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has commenced a …Web24 Agu 2021 ... The Court agrees with Plaintiffs' arguments. The Court has found that Plaintiffs adequately alleged that Corcept utilized an off-label marketing ...Corcept’s first quarter 2023 revenue was $105.7 million, compared to $93.7 million in the first quarter of 2022. First quarter operating expenses were $90.8 million, compared to $66.9 million in ...Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today …Web13 Nov 2023 ... Teva Pharmaceutical Industries Ltd. urged a federal judge to reject Corcept Therapeutics Inc.'s request to reopen the trial record for new ...Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical …WebDec 8, 2022 · Since 2012, Corcept has made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym was the first FDA-approved treatment for that illness. About Corcept Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021; Results show statistically significant and clinically relevant benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept’s …WebCorcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking StatementsOn November 2, 2023, Joseph Lyon, the Chief Accounting Officer of Corcept Therapeutics Inc (NASDAQ:CORT), sold 5,000 shares of the company. Find the latest Corcept Therapeutics Incorporated (CORT ...

November 2023 – PROPRIETARY – Do not republish, redistribute or modify without Corcept’s express written permission This presentation contains forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, and the Securities Act of 1933, as amended. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...Web8/3/2022. Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended June 30, 2022. First.WebInstagram:https://instagram. reit return calculatorvacation rental insurance state farmis blue shield insurance goodcyclical stock list Jul 26, 2023 · November 1, 2023. Corcept Appoints Monica Tellado as President, Emerging Markets. October 26, 2023. Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH) October 25, 2023. Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call. August 2, 2023. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ... pjetatandt dividend stock Jul 5, 2022 11:14AM EDT. Corcept Therapeutics Incorporated 's CORT only marketed drug, Korlym, has been approved for the once-daily oral treatment of hyperglycemia — secondary to ...Web2015-10000 12/17/2015 Closed LATHAM & WATKINS LLP 11104397 11063344 10989897 ETC 2015-10001 Steptoe & Johnson LLP FAP 2258 2015-10002 HemoCue AB K142209 tlt stock dividend Corcept plans to submit these results for presentation at a scientific conference. Corcept will initiate a Phase 2b trial in the fourth quarter to further study this dosing regimen. “Miricorilant is highly active in the liver with a unique mechanism of action and holds great promise for the treatment of NASH,” said Naim Alkhouri , MD ...WebCorcept’s first quarter 2023 revenue was $105.7 million, compared to $93.7 million in the first quarter of 2022. First quarter operating expenses were $90.8 million , compared to $66.9 million in the first quarter of 2022, due to increased spending on …Cortisol. Cortisol is a hormone that modulates many physiological and psychological processes. Because of its central role in the body’s response to stress, cortisol is most commonly known as the stress hormone. It plays a key role in regulating metabolism and maintaining normal blood pressure. It affects both cognition and emotional state.